SE8801426D0 - METHOD AND METHOD OF BLOOD TREATMENT - Google Patents
METHOD AND METHOD OF BLOOD TREATMENTInfo
- Publication number
- SE8801426D0 SE8801426D0 SE8801426A SE8801426A SE8801426D0 SE 8801426 D0 SE8801426 D0 SE 8801426D0 SE 8801426 A SE8801426 A SE 8801426A SE 8801426 A SE8801426 A SE 8801426A SE 8801426 D0 SE8801426 D0 SE 8801426D0
- Authority
- SE
- Sweden
- Prior art keywords
- blood
- mitogen
- blood sample
- vitro
- bodies
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
- B29C45/17—Component parts, details or accessories; Auxiliary operations
- B29C45/64—Mould opening, closing or clamping devices
- B29C45/66—Mould opening, closing or clamping devices mechanical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
- B29C45/17—Component parts, details or accessories; Auxiliary operations
- B29C45/64—Mould opening, closing or clamping devices
- B29C45/66—Mould opening, closing or clamping devices mechanical
- B29C2045/667—Cam drive for mould closing or clamping
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Manufacturing & Machinery (AREA)
- Mechanical Engineering (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An immuno-stimulating blood preparation, suitable for e.g. tumor therapy, is prepared by incubating a cell-containing blood sample, especially whole blood, taken from a specific individual, with a mitogen in vitro to produce a blood preparation designed to be re-administered to the same individual. The method comprises the further step of removing anti-bodies, which are specific for the mitogen used, from the blood sample before the incubation with the mitogen in vitro. The anti-bodies are preferably removed by contacting the blood sample with the corresponding mitogen or its active derivatives or active immobilized forms of the mitogen. Preferred mitogen such as SEA have a strong specificity for MHC II on accessory cells such as monocytes and/or B cells. A blood treatment kit for carrying out the method comprises at least one blood container having a blood sample inlet and a blood sample outlet, separation means provided in said outlet, and means for contacting said blood sample with at least one agent having mitogenic activity in the blood container. The separation means are preferably capable of separating the mitogen from the blood sample to make the treated blood sample substantially free from mitogenic activity.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8801426A SE8801426D0 (en) | 1988-04-15 | 1988-04-15 | METHOD AND METHOD OF BLOOD TREATMENT |
PCT/SE1989/000208 WO1989009619A1 (en) | 1988-04-15 | 1989-04-14 | Method and means for immuno-stimulating blood treatment with mitogen |
JP1504245A JPH03503640A (en) | 1988-04-15 | 1989-04-14 | Methods and means of blood processing |
AU34206/89A AU632999B2 (en) | 1988-04-15 | 1989-04-14 | Method and means for immuno-stimulating blood treatment with a mitogen |
KR1019890702371A KR900700131A (en) | 1988-04-15 | 1989-04-14 | Method and apparatus for immunostimulatory blood treatment by mitosis |
EP19890904646 EP0406317A1 (en) | 1988-04-15 | 1989-04-14 | Method and means for immuno-stimulating blood treatment with mitogen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8801426A SE8801426D0 (en) | 1988-04-15 | 1988-04-15 | METHOD AND METHOD OF BLOOD TREATMENT |
Publications (1)
Publication Number | Publication Date |
---|---|
SE8801426D0 true SE8801426D0 (en) | 1988-04-15 |
Family
ID=20372041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8801426A SE8801426D0 (en) | 1988-04-15 | 1988-04-15 | METHOD AND METHOD OF BLOOD TREATMENT |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0406317A1 (en) |
JP (1) | JPH03503640A (en) |
KR (1) | KR900700131A (en) |
AU (1) | AU632999B2 (en) |
SE (1) | SE8801426D0 (en) |
WO (1) | WO1989009619A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
SE8903100D0 (en) * | 1989-09-20 | 1989-09-20 | Pharmacia Ab | NEW PHARMACEUTICAL AGENT |
US5728388A (en) * | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
EP0511306B1 (en) * | 1990-01-17 | 2002-07-17 | TERMAN, David S. | Tumor killing effects of enterotoxins and related compounds |
AU6358994A (en) * | 1993-03-02 | 1994-09-26 | David S. Terman | Method of cancer treatment |
ATE287270T1 (en) * | 1994-11-17 | 2005-02-15 | Univ South Florida | METHOD FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING SECONDARY IMMUNE DEFICIENCY |
WO2002034119A2 (en) | 2000-10-27 | 2002-05-02 | Immuno-Rx, Inc. | Vaccine immunotherapy for immune suppressed patients |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
EP2234642B8 (en) | 2007-11-28 | 2017-11-01 | IRX Therapeutics, Inc. | Method of increasing immunological effect |
ES2679043T3 (en) | 2009-05-15 | 2018-08-21 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
CN107050430B (en) | 2009-12-08 | 2021-10-15 | 伊尔克斯治疗有限公司 | Method for reversing Langerhans cell immunosuppression |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU570911B2 (en) * | 1981-11-06 | 1988-03-31 | Baylor College Of Medicine | Immunoadsorbent based on immobilized protein a and its use |
CA1204667A (en) * | 1982-10-04 | 1986-05-20 | Masashi Kodama | Blood treating material |
DE3476634D1 (en) * | 1983-06-13 | 1989-03-16 | Ragnvald Erik Lindblom | A method of treating interferon sensitive diseases, and a method and a device for preparing a _g(g)-interferon containing preparation |
US4551435A (en) * | 1983-08-24 | 1985-11-05 | Immunicon, Inc. | Selective removal of immunospecifically recognizable substances from solution |
DE3483252D1 (en) * | 1983-12-05 | 1990-10-25 | Asahi Chemical Ind | METHOD FOR THE INDUCTION OF ANTITUM IMMUNOCYTES, METHOD FOR THE PRODUCTION OF ANTITUM IMMUNOCYTES AND ANTITUM IMMUNOCYTS PRODUCED BY THE METHOD. |
JPH01308300A (en) * | 1988-01-25 | 1989-12-12 | American Cyanamid Co | Heparine bondable brain mitogen |
WO1989007448A1 (en) * | 1988-02-12 | 1989-08-24 | Regents Of The University Of California | Use of synthetic peptides to generate and manipulate cellular immunity |
-
1988
- 1988-04-15 SE SE8801426A patent/SE8801426D0/en unknown
-
1989
- 1989-04-14 AU AU34206/89A patent/AU632999B2/en not_active Ceased
- 1989-04-14 WO PCT/SE1989/000208 patent/WO1989009619A1/en not_active Application Discontinuation
- 1989-04-14 JP JP1504245A patent/JPH03503640A/en active Pending
- 1989-04-14 EP EP19890904646 patent/EP0406317A1/en not_active Withdrawn
- 1989-04-14 KR KR1019890702371A patent/KR900700131A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU632999B2 (en) | 1993-01-21 |
KR900700131A (en) | 1990-08-11 |
EP0406317A1 (en) | 1991-01-09 |
JPH03503640A (en) | 1991-08-15 |
AU3420689A (en) | 1989-11-03 |
WO1989009619A1 (en) | 1989-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Metcalf et al. | Formation of eosinophilic‐like granulocytic colonies by mouse bone marrow cells in vitro | |
US4444887A (en) | Process for making human antibody producing B-lymphocytes | |
RAPOPORT | Dog thyroid cells in monolayer tissue culture: adenosine 3', 5'-cyclic monophosphate response to thyrotropic hormone | |
Zanetta et al. | The presence of 2′, 3′‐cyclic AMP 3′‐phosphohydrolase in glial cells in tissue culture | |
Sugiura et al. | Wheat germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have potent natural suppressor activity. | |
Okada et al. | The differentiation of cytotoxic T cells in vitro: I. Amplifying factor (s) in the primary response is Lyt 1+ cell dependent | |
US4390623A (en) | Serum-free and mitogen-free T-cell growth factor and process for making same | |
Goldschneider et al. | Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen. | |
AU9058091A (en) | Preparation of nucleic acid samples | |
WO1996023060B1 (en) | Method for isolating dendritic cells | |
Vallee et al. | Purification of microtubules and microtubule-associated proteins from sea urchin eggs and cultured mammalian cells using taxol, and use of exogenous taxol-stabilized brain microtubules for purifying microtubule-associated proteins | |
SE8801426D0 (en) | METHOD AND METHOD OF BLOOD TREATMENT | |
ES2132063T3 (en) | PROCEDURE FOR THE CAPTURE AND RECOVERY OF CELLS. | |
DE3886254D1 (en) | Apparatus for the treatment of biological samples and treatment methods with the apparatus. | |
Stasny et al. | The effect of sonic oscillation on the structure and function of beef heart mitochondria | |
Kahan | Isolation of a soluble transplantation antigen | |
Pope et al. | Two distinct populations of suppressor cells in the spleens of mice bearing methylcholanthrene-induced tumors | |
EP0049611B1 (en) | A t-cell growth factor, and a process of producing the same | |
Askanas et al. | Histochemistry of cultured aneural chick muscle. Morphological maturation without differentiation of fiber types | |
Altman et al. | Natural cell-mediated cytotoxicity in guinea pigs: properties and specificity of natural killer cells | |
Basch et al. | Thymopoietin-induced acquisition of responsiveness to T cell mitogens | |
ES8501630A1 (en) | In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins. | |
ATE76751T1 (en) | PROCEDURE FOR ISOLATION OF BLOOD COAGULATION FACTOR IX. | |
Moskalewski et al. | Presence of egg antigen in immature oocytes and preimplantation embryos | |
Tsang et al. | Modulation of T-and B-lymphocyte functions by isoprinosine in homosexual subjects with prodromata and in patients with acquired immune deficiency syndrome (AIDS) |